Sustainability through Evidence-Based Equations: A Pilot Study Modeling the Friedewald and NIH-Sampson Equations [0.03%]
基于证据的公式化可持续性研究：弗里德瓦尔德和NIH-桑普森公式的建模试点研究
Stephanie A Hart,Joesph R Wiencek
Stephanie A Hart
Assessment of TIMP1, Transgelin-2, and Procalcitonin as Protein Biomarkers for Diagnosis and Prognosis of Bloodstream Infection in a Critically Ill Cohort [0.03%]
TIMP1、transgelin-2和procalcitonin作为诊断和预测危重患者血流感染的蛋白质生物标志物的价值评估
Sajal Tiwary,Caroline A O&#x;Neil,Sydney Lawless et al.
Sajal Tiwary et al.
Background: Bloodstream infections (BSI) are a significant contributor to morbidity and mortality among hospitalized patients. Rapid diagnosis of BSI is critical for timely and appropriate clinical management, but current...
Sixth Generation High-Sensitivity Cardiac Troponin T: Will a Better Assay Make a Better Biomarker? [0.03%]
第六代高敏心肌肌钙蛋白T检测：更好的检测能否造就更佳的标志物？
Amber Pollock,Alexander J F Thurston,Andrew R Chapman et al.
Amber Pollock et al.
AI'm Here to Help: Enhancing Laboratory Genetic Counseling with Artificial Intelligence [0.03%]
“AI助您：用人工智能增强实验室遗传咨询”
Zöe Powis,Khalida Liaquat,Matthew L Tschirgi
Zöe Powis
Background: Artificial intelligence (AI) is transforming the fields of genetics and genetic counseling, enhancing both clinical and laboratory practices. The rise of AI technologies has drawn attention to their potential ...
Analytical Performance of the Sixth Generation High-Sensitivity Cardiac Troponin T Assay [0.03%]
第六代高敏肌钙蛋白T检测的性能评估分析
Mengyuan Ge,Lori B Daniels,Spencer Seely et al.
Mengyuan Ge et al.
Background: High-sensitivity cardiac troponin assays are integral to diagnosing myocardial infarction. The current Roche Elecsys® Troponin T high-sensitivity Gen 5 assay (Gen 5) received FDA clearance in 2017. A sixth-ge...
Result Interpretation in Skewed Populations-Are Common Reference Intervals Inadequate? [0.03%]
偏斜人群的结果解读-常见的参考区间是否不够用？
Dennis J Orton,Jessica L Gifford,Gregory A Kline
Dennis J Orton
Background: Reference intervals (RIs) are defined as the central 95th percentile of a healthy population, and many biomarkers exhibit a skewed result distribution. Here we demonstrate interpretive variations for results f...
Addressing Diagnostics Delay in Multiple Myeloma: Insights from a National Survey of Primary Care Providers [0.03%]
全国初级保健提供者多发性骨髓瘤诊断延迟调查的见解
Bhrugu Yagnik,Jill Pauli,Brittany Watson et al.
Bhrugu Yagnik et al.
Background: Our aim was to assess the knowledge, awareness, and confidence of US primary care providers (PCPs) in assessing multiple myeloma (MM) and related plasma cell disorders. ...
Agreement Statistics for Methods Comparison Based on Total Error Per CLSI EP46 and FDA Assay Criteria Using Web Tool [0.03%]
基于CLSI EP46和FDA标准使用在线工具进行方法学对比的总误差一致性统计分析
Lawrence I Kuei Lin
Lawrence I Kuei Lin
Background: Per CLSI EP46 (2025), the validation of a test device, when compared to a reference device, should focus on evaluating the total analytical error (TAE) and show that it is within an allowable total error (ATE)...
Sample Size Guidance and Justification for Studies of Biological Variability [0.03%]
生物变异性研究的样本量指导和合理性分析
Alice J Sitch,Jacqueline Dinnes,Sue Mallett et al.
Alice J Sitch et al.
Background: Good estimates of analytical, within-subject, and between-subject variation, from appropriately designed biological variability studies, allow the potential for a biomarker to diagnose and monitor disease to b...